Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA's Final Rule On IND Safety Reporting Encourages More Limited Submissions

This article was originally published in The Pink Sheet Daily

Executive Summary

Revisions emphasize the types of evidence that suggest a causal relationship between the drug and adverse event.
Advertisement

Related Content

Post-Market Safety Updates Replaced By “Periodic Benefit-Risk Evaluation Reports”
FDA's Rulemaking To-Do List Includes Dampening Pedigrees, Boosting Electronic Labeling
FDA's Rulemaking To-Do List Includes Dampening Pedigrees, Boosting Electronic Labeling
IND Safety Reporting Rule Delayed After PhRMA Asks For More Harmonization
IND Safety Reporting Rule Delayed After PhRMA Asks For More Harmonization
FDA IND Safety Reporting Rule: New Types Of Data Must Be Submitted
FDA IND Safety Reporting Rule: New Types Of Data Must Be Submitted
Foreign Safety Data Sought By FDA Under Proposed Rule On Periodic Updates
Foreign Safety Data Sought By FDA Under Proposed Rule On Periodic Updates

Topics

Advertisement
UsernamePublicRestriction

Register

PS071247

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel